GlobeNewswire·Oct 16, 2025, 8:30 AM ET

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

Aligos Therapeutics announced that the USAN Council adopted pevifoscorvir sodium as the nonproprietary name for its investigational compound ALG-000184.
The new name, which may be referred to as "pevy," marks the first generic name adopted for a compound at Aligos.
Pevifoscorvir sodium is a potent oral small molecule capsid assembly modulator (CAM-E) derived from IP licensed from Dr. Raymond Schinazi at Emory University.
Phase 1 studies demonstrated that pevifoscorvir sodium was well-tolerated with no safety signals, linear pharmacokinetics, & excellent antiviral activity.
Long-term Phase 1 studies showed sustained reductions in HBV DNA, RNA, HBsAg, HBeAg, & HBcrAg over 96 weeks of dosing.
The FDA, EMA, & NMPA have acknowledged a regulatory path for pevifoscorvir sodium utilizing the chronic suppressive pathway.
Final & post-treatment follow-up data from the 96-week Phase 1 dosing study are expected at AASLD The Liver Meeting in 2025.
The Phase 2 B-SUPREME study initiated in August 2025, with interim data projected for 2026 & topline data anticipated in 2027.
Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on therapies for liver & viral diseases, including chronic HBV, MASH, & coronaviruses.